Welzel Tatjana, Kuemmerle-Deschner Jasmin, Sluka Constantin, Carlomagno Raffaella, Cannizzaro Schneider Elvira, Kaiser Daniela, Hofer Michael, Hentgen Veronique, Woerner Andreas
Pediatric Rheumatology, University Children's Hospital Basel, University of Basel, Basel, Switzerland.
Department of Pediatrics, Division of Pediatric Rheumatology, Autoinflammation Reference Center Tuebingen (arcT), University Hospital Tuebingen, Tuebingen, Germany.
Front Pediatr. 2022 Sep 8;10:993811. doi: 10.3389/fped.2022.993811. eCollection 2022.
Children with pediatric inflammatory rheumatic diseases (PRD) have an increased infection risk. Vaccinations are effective to avoid vaccine-preventable diseases. This study aimed to assess the vaccination completeness in Swiss PRD patients stratified by immunosuppressive treatment (IST).
This multicenter observational cohort study of PRD patients was performed in Basel, Geneva, Lucerne, Lausanne, and Zurich in PRD patients aged < 18 years included in the Juvenile Inflammatory Rheumatism Cohort. Completeness was assessed for i) the overall vaccination status (Swiss national immunization program (NIP) and specific additional PRD-recommended vaccinations), ii) for all and each vaccination of the NIP at PRD diagnosis and reference date (RefD) and iii) all and each specific additional PRD-recommended vaccination at RefD. Completeness was assessed over the disease course and stratified by IST.
Of 616 eligible patients, 234 children were analyzed. Of these, 147 (63%) were girls. Median age at PRD diagnosis was 6.5 years (IQR 2.9-10.3) and 10.9 years at RefD (6.9-14.3). The median follow-up since PRD diagnosis was 3 years (1.1-5.5). 120/234 children received IST. At RefD, overall vaccination completeness was 3.8% (9/234 children), completeness for the NIP vaccinations was 70.1% (164/234 children; IST 65%, no IST: 75.4%) and for all specific additional PRD-recommended vaccinations was 3.8% (9/234 children; IST 2.5%; no IST 5.3%). Vaccination completeness against pneumococcal disease, hepatitis B virus, and human papilloma virus (HPV) was 50.4, 20, 37.9%, respectively. In 25/35 children with negative varicella zoster virus history vaccination status was complete (IST: 94.4%, no IST: 47%). Annual non-live influenza vaccination was complete in 24.2% of children during IST; adherence decreased over the disease course.
This study identified a low overall vaccination completeness in children with PRD. Particularly, the completeness of specific additional PRD-recommended vaccinations was low. If not performed early after PRD diagnosis, vaccination status remained frequently incomplete. Close collaboration between pediatrician and rheumatologist to improve vaccination completeness is essential. Exchange of vaccination records, standardized assessment of specific PRD-recommended vaccinations and those of the NIP, and annual reminder for influenza vaccination are crucial to improve vaccination completeness in this vulnerable pediatric population.
患有儿童炎性风湿性疾病(PRD)的儿童感染风险增加。疫苗接种对于预防疫苗可预防疾病有效。本研究旨在评估按免疫抑制治疗(IST)分层的瑞士PRD患者的疫苗接种完整性。
这项针对PRD患者的多中心观察性队列研究在巴塞尔、日内瓦、卢塞恩、洛桑和苏黎世对纳入青少年炎性风湿病队列的18岁以下PRD患者进行。评估了以下方面的完整性:i)总体疫苗接种状况(瑞士国家免疫规划(NIP)和PRD特别推荐的额外疫苗接种),ii)在PRD诊断和参考日期(RefD)时NIP的所有及每种疫苗接种,以及iii)在RefD时所有及每种PRD特别推荐的额外疫苗接种。在疾病过程中评估完整性并按IST分层。
在616名符合条件的患者中,分析了234名儿童。其中,147名(63%)为女孩。PRD诊断时的中位年龄为6.5岁(四分位间距2.9 - 10.3),RefD时为10.9岁(6.9 - 14.3)。自PRD诊断以来的中位随访时间为3年(1.1 - 5.5)。120/234名儿童接受了IST。在RefD时,总体疫苗接种完整性为3.8%(9/234名儿童),NIP疫苗接种的完整性为70.1%(164/234名儿童;IST组为65%,非IST组为75.4%),所有PRD特别推荐的额外疫苗接种的完整性为3.8%(9/234名儿童;IST组为2.5%;非IST组为5.3%)。针对肺炎球菌疾病、乙型肝炎病毒和人乳头瘤病毒(HPV)的疫苗接种完整性分别为50.4%、20%、37.9%。在水痘带状疱疹病毒病史阴性的35名儿童中,25名的疫苗接种状况完整(IST组:94.4%,非IST组:47%)。在接受IST治疗的儿童中,24.2%完成了年度非活流感疫苗接种;依从性在疾病过程中有所下降。
本研究发现PRD儿童的总体疫苗接种完整性较低。特别是,PRD特别推荐的额外疫苗接种的完整性较低。如果在PRD诊断后未尽早进行,疫苗接种状况往往仍不完整。儿科医生和风湿病学家密切合作以提高疫苗接种完整性至关重要。疫苗接种记录的交换、对PRD特别推荐疫苗接种和NIP疫苗接种的标准化评估以及年度流感疫苗接种提醒对于改善这一脆弱儿科人群的疫苗接种完整性至关重要。